Menu
D

Detroit Clinical Research Center | Farmington Hills, MI

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

RHB-105
Luspatercept
Milvexian
REGN7075
Droxidopa
Farletuzumab
EG12014
Platinum
Abraxane
Guselkumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned.The aim is to find...

Enrolling
Non-Small Cell Lung Cancer
Drug: Cemiplimab
Drug: REGN7075

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in...

Active, not recruiting
Colitis, Ulcerative
Drug: Guselkumab Dose 2
Other: Placebo

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling
Ischemic Stroke; Ischemic Attack, Transient
Drug: Placebo
Drug: Milvexian
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trial sponsors

Celgene logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Acorda Therapeutics logo
A
Bayer logo
CSL Behring logo
E
G
Lilly logo